Modality
siRNA
MOA
SOS1i
Target
GPRC5D
Pathway
Amyloid
ObesityMigraine
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
Oct 2021
→ Nov 2025
Phase 2Current
NCT03578136
2,358 pts·Obesity
2021-10→2025-11·Recruiting
2,358 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-055mo agoPh2 Data· Obesity
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2025-11-05 · 5mo ago
Obesity
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03578136 | Phase 2 | Obesity | Recruiting | 2358 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |